Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 18Dermatologic 13Gastrointestinal 8Thoracic 6Plasma cell 4Other hematologic neoplasm 4Head & Neck 4CNS 4Lymphoid 3Myeloid 2Gynecologic 2Endocrine 2Breast 2Sarcoma 1Other solid neoplasm 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Osteosarcoma 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × trametinib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡